Michael G. Kelly

Michael G. Kelly

Chief Tech/Sci/R&D Officer at CureDuchenne

Health Technology
Consumer Services
Finance

Profile

Michael G.
Kelly
is currently the Director at Trinds LLC since 2017 and the Chief Scientific Officer at CureDuchenne since 2011.
Previously, he worked as the President, Chief Executive Officer & Director at MyoTherix, Inc. He was also the Research Director at Amgen, Inc. from 1999 to 2000.
Additionally, he worked as a Director at NeoGenesis Pharmaceuticals, Inc. and as the Senior Vice President-Research & Development at Renovis, Inc. Dr. Kelly holds a doctorate degree from The University of Southampton and an undergraduate degree from the University of Ulster.

Michael G. Kelly active positions

CompaniesPositionStart
Chief Tech/Sci/R&D Officer 2011-12-12
Director/Board Member 2017-10-31
All active positions of Michael G. Kelly

Former positions of Michael G. Kelly

CompaniesPositionEnd
AMGEN INC. Chief Tech/Sci/R&D Officer 1999-12-31
Chief Tech/Sci/R&D Officer -
Director/Board Member -
Chief Executive Officer -
See the detail of Michael G. Kelly's experience

Training of Michael G. Kelly

The University of Southampton Doctorate Degree
University of Ulster Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael G. Kelly's experience

Connections

57

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
AMGEN INC.

Health Technology

Private companies5

Health Technology

Health Technology

Finance

Health Technology

Commercial Services

See company connections
  1. Stock Market
  2. Insiders
  3. Michael G. Kelly